Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data
Circulation · 31.03.2026 · 153 (13) · 980-982
DOI: 10.1161/circulationaha.126.079012 ↗Kurz gefasst
Editorial in der Zeitschrift Circulation, erschienen am 31.03.2026. Verfasst von Jonah D Garry und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FDA HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN.
ORCID-Profile: Jonah D Garry, Evan L Brittain
Förderung
- FDA HHS
- NHLBI NIH HHS
Zitieren
APA
Garry, J. D., & Brittain, E. L. (2026). Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data. Circulation, 153(13), 980-982. https://doi.org/10.1161/circulationaha.126.079012
Vancouver
Garry JD, Brittain EL. Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data. Circulation. 2026;153(13):980-982. doi:10.1161/circulationaha.126.079012
BibTeX
@article{Garry2026,
author = {Garry, Jonah D and Brittain, Evan L},
title = {Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data},
journal = {Circulation},
year = {2026},
volume = {153},
number = {13},
pages = {980--982},
doi = {10.1161/circulationaha.126.079012}
}
EUVIMED